Table of Contents
Table of Contents 2

Introduction 7
Global Markets Direct Report Coverage 7
Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) Overview 8
Therapeutics Development 9
Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Products under Development by Stage of Development 9
Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Products under Development by Therapy Area 10
Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Products under Development by Indication 11
Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Products under Development by Companies 14
Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Therapeutics Assessment 17
Assessment by Monotherapy/Combination Products 17
Assessment by Mechanism of Action 18
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Companies Involved in Therapeutics Development 23
Actelion Ltd 23
Arena Pharmaceuticals, Inc. 24
AstraZeneca Plc 25
Celgene Corporation 26
GlaxoSmithKline Plc 27
Meiji Seika Pharma Co., Ltd. 28
Novartis AG 29
Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Drug Profiles 30
AKP-11 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
APD-334 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
BMS-986104 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
CBP-307 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Cenerimod - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
CP-9531 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
NIBR-0213 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
ozanimod hydrochloride - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
ponesimod - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
siponimod - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Small Molecule to Agonize S1P1 for Multiple Sclerosis - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Small Molecule to Agonize S1PR1 for Multiple Sclerosis - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Small Molecule to Agonize S1PR1 for Ulcerative Colitis - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
Small Molecule to Antagonize Sphingosine 1 Phosphate Receptor 1 for Oncology - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Small Molecule to Modulate S1PR1 for Atopic Dermatitis - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Dormant Projects 55
Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Discontinued Products 57
Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Featured News & Press Releases 58
May 04, 2016: Study Shows Ozanimod as Effective in Treating Ulcerative Colitis 58
Mar 18, 2016: Oral Ozanimod Showed Histologic Improvements in Patients with Ulcerative Colitis in the Phase 2 TOUCHSTONE Trial 59
Feb 18, 2016: Oral Ozanimod 72-Week Phase 2 Results From RADIANCE Trial in Relapsing Multiple Sclerosis Presented At ACTRIMS 60
Jan 08, 2016: Suzhou Connect Biopharma Reports Positive Phase 1b Result for Novel S1P1 Modulator CBP-307 for Autoimmune Diseases 61
Dec 14, 2015: Akaal Pharma Announces Superior Safety and Comparable Efficacy of Sphingosine 1-Phosphate Receptor-1 (S1P1) Modulator AKP-11 as Compared to Gilenya (Fingolimod) for the Treatment of Multiple Sclerosis 62
Dec 14, 2015: US Patents Issued to Akaal Pharma on S1P1 Receptor Modulators Useful for the Treatment of Autoimmune and Inflammatory Diseases 63
Oct 26, 2015: Phase 2 Maintenance Data from Oral Ozanimod TOUCHSTONE Study in Ulcerative Colitis Presented at UEG Week 63
Oct 19, 2015: Phase 2 Maintenance Data from Oral Ozanimod TOUCHSTONE Study in Ulcerative Colitis Presented at ACG Plenary Session 65
Sep 01, 2015: MS Trial Alert: Investigators Recruiting Worldwide for Phase III Clinical Trial of Oral Ponesimod 66
Jul 30, 2015: Suzhou Connect Biopharma Reports Positive Phase 1a Results for CBP-307, a Novel, Orally-active S1P1 Modulator for Autoimmune Diseases 66
Jul 29, 2015: Arena Pharmaceuticals Initiates a Phase 2 Clinical Trial of APD334, its S1P1 Receptor Modulator for Autoimmune Diseases 67
Jul 09, 2015: Suzhou Connect Biopharma Announces Patent Issuance Covering CBP-307 - a Clinical-stage Second Generation S1P1 Immune Modulator 67
Jul 01, 2015: Akaal Pharma, Australia extends collaboration with GVK BIO for formulations development services to support Phase 2 Clinical studies for Topical Treatment of Psoriasis 68
Jun 25, 2015: New Data Supporting Gradual Up-Titration Of Ponesimod To Mitigate First-Dose Cardiodynamic Effects To Be Presented At Eacpt 2015 68
Jun 16, 2015: Akaal Pharma Receives Approval to Initiate Phase 2 Clinical Trial for the Topical Treatment of Psoriasis 69
Appendix 70
Methodology 70
Coverage 70
Secondary Research 70
Primary Research 70
Expert Panel Validation 70
Contact Us 70
Disclaimer 71

List of Tables
Number of Products under Development for, H1 2016 9
Number of Products under Development by Therapy Area, H1 2016 10
Number of Products under Development by Indication, H1 2016 11
Comparative Analysis by Late Stage Development, H1 2016 12
Comparative Analysis by Early Stage Products, H1 2016 13
Number of Products under Development by Companies, H1 2016 14
Products under Development by Companies, H1 2016 15
Products under Development by Companies, H1 2016 (Contd..1) 16
Assessment by Monotherapy/Combination Products, H1 2016 17
Number of Products by Stage and Mechanism of Action, H1 2016 19
Number of Products by Stage and Route of Administration, H1 2016 21
Number of Products by Stage and Molecule Type, H1 2016 22
Pipeline by Actelion Ltd, H1 2016 23
Pipeline by Arena Pharmaceuticals, Inc., H1 2016 24
Pipeline by AstraZeneca Plc, H1 2016 25
Pipeline by Celgene Corporation, H1 2016 26
Pipeline by GlaxoSmithKline Plc, H1 2016 27
Pipeline by Meiji Seika Pharma Co., Ltd., H1 2016 28
Pipeline by Novartis AG, H1 2016 29
Dormant Projects, H1 2016 55
Dormant Projects (Contd..1), H1 2016 56
Discontinued Products, H1 2016 57

List of Figures
Number of Products under Development for, H1 2016 9
Number of Products under Development by Therapy Area, H1 2016 10
Number of Products under Development by Top 10 Indication, H1 2016 11
Comparative Analysis by Late Stage Development, H1 2016 12
Comparative Analysis by Early Stage Products, H1 2016 13
Assessment by Monotherapy/Combination Products, H1 2016 17
Number of Products by Mechanism of Actions, H1 2016 18
Number of Products by Stage and Mechanism of Actions, H1 2016 18
Number of Products by Routes of Administration, H1 2016 20
Number of Products by Stage and Routes of Administration, H1 2016 20
Number of Products by Stage and Molecule Type, H1 2016 22

Companies Mentioned
Actelion Ltd
Arena Pharmaceuticals, Inc.
AstraZeneca Plc
Celgene Corporation
GlaxoSmithKline Plc
Meiji Seika Pharma Co., Ltd.
Novartis AG